Enanta Pharmaceuticals (ENTA) Cash & Equivalents (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Cash & Equivalents data on file, last reported at $34.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 41.99% year-over-year to $34.9 million; the trailing twelve-month figure through Mar 2026 stood at $34.9 million (down 41.99% YoY), and the FY2025 full-year result was $32.3 million, down 13.25% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $34.9 million, down from $37.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $95.2 million in Q2 2023 and bottomed at $28.4 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $42.2 million (2022), against an average of $51.8 million.
• The widest annual swing landed in 2022, when Cash & Equivalents jumped 516.54%; it then slumped 62.41% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $42.2 million in 2022, then decreased by 5.42% to $39.9 million in 2023, then jumped by 111.23% to $84.3 million in 2024, then plunged by 55.62% to $37.4 million in 2025, then decreased by 6.7% to $34.9 million in 2026.
• The last three Cash & Equivalents figures came in at $34.9 million (Q1 2026), $37.4 million (Q4 2025), and $32.3 million (Q3 2025), per Business Quant data.

Peer Comparison